Johnson & Johnson aspires to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color. The Company commits $100M over the next five years to invest in and promote health equity solutions.

An estimated 83,570 excess deaths each year could be prevented in the United States if the black-white mortality gap could be eliminated.1

Black Americans continue to experience the highest COVID-19 mortality rates nationwide.2

The population of Latinx and Black active physicians and clinical trial participants are underrepresented compared to the national makeup of the United States.3,4

Black adults are up to two times more likely to develop high blood pressure by age 55 compared to white adults, with many of these racial differences developing before age 30.5

70% of Black Americans believe that the healthcare system treats people unfairly based upon their race or ethnic background, compared to 41% of white Americans.6

If COVID-19 impacted diverse populations at the same rate as white Americans, about 21,800 Black, 11,400 Latinx, 750 Indigenous & 65 Pacific Islander Americans would still be alive.7

5 Black CEOs make up just 1% of the Fortune 500 despite African Americans representing 13.4% of the US population.8

A Federal Reserve study estimates that 41% of Black-owned businesses in the United States closed between February and April 2020.9

More than a third of Black (40%) and Latinx (37%) STEM students switch majors before earning a degree, compared with 29% of white STEM students.10